Review -: Induction of prostate apoptosis by α1-adrenoceptor antagonists:: mechanistic significance of the quinazoline component

被引:66
作者
Anglin, IE
Glassman, DT
Kyprianou, N
机构
[1] Univ Maryland, Med Ctr, Div Urol, Dept Surg,Sch Med, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Mol Biol & Biochem, Baltimore, MD 21201 USA
关键词
prostate; apoptosis; adrenoceptor antagonist; quinazoline; TGF-beta;
D O I
10.1038/sj.pcan.4500561
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
alpha(1)-Adrenoceptor antagonists, have been documented to induce apoptosis and reduce prostate tumor vascularity in benign and malignant prostate cells. The quinazoline based alpha(1)-antagonists, doxazosin and terazosin but not tamsulosin (a sulphonamide derivative) suppress prostate growth without affecting cell proliferation. These quinazoline-mediated apoptotic effects occur via an alpha(1)-adrenoceptor independent mechanism potentially involving activation of the TGF-beta signal transduction pathway. This review discusses the current knowledge of the action of quinazoline-derived alpha(1)-adrenoceptor antagonists in the benign and malignant prostate and their potential therapeutic use in the treatment of benign prostatic hyperplasia (BPH) and prostate cancer. Finally, a molecular pathway is proposed for their observed apoptotic function against prostate cells. Increased understanding of the action of these established and clinically accepted agents would provide a basis for the design of safe, effective therapeutic regimens in the treatment of prostatic diseases.
引用
收藏
页码:88 / 95
页数:8
相关论文
共 92 条
[31]  
Furuya Y, 1996, CLIN CANCER RES, V2, P389
[32]  
Glassman DT, 2001, PROSTATE, V46, P45, DOI 10.1002/1097-0045(200101)46:1<45::AID-PROS1007>3.0.CO
[33]  
2-U
[34]   ErbB kinases and NDF signaling in human prostate cancer cells [J].
Grasso, AW ;
Wen, DZ ;
Miller, CM ;
Rhim, JS ;
Pretlow, TG ;
Kung, HJ .
ONCOGENE, 1997, 15 (22) :2705-2716
[35]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33
[36]  
Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.0.CO
[37]  
2-D
[38]  
Guo YP, 1998, CELL GROWTH DIFFER, V9, P185
[39]   The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-κB (NF-κB)-inducing kinase to activate NF-κB -: Identification of a novel receptor-tyrosine kinase signalosome [J].
Habib, AA ;
Chatterjee, S ;
Park, SK ;
Ratan, RR ;
Lefebvre, S ;
Vartanian, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (12) :8865-8874
[40]  
Harper ME, 1998, J PATHOL, V186, P169, DOI 10.1002/(SICI)1096-9896(1998100)186:2<169::AID-PATH164>3.0.CO